SHOUHUI GROUP (02621) released its annual performance for 2025, with shareholders' net profit at 793 million yuan.
Hande Group (02621) announced its annual financial results for the year ending December 31, 2025. The revenue was 1.469 billion RMB, an increase of 5.9% compared to the previous year. The profit attributable to equity shareholders of the company was 793 million RMB, a turnaround from a loss of 136 million RMB in the same period last year. The basic earnings per share were 4.70 RMB, and the proposed final dividend was 0.14 Hong Kong dollars per share (including tax).
SHOUHUI GROUP (02621) announced its financial performance for the year ending December 31, 2025, with revenue of 1.469 billion RMB, a year-on-year increase of 5.9%; the profit attributable to equity shareholders of the company was 793 million RMB, compared to a loss of 136 million RMB in the same period last year; basic earnings per share were 4.70 RMB, with a proposed final dividend of 0.14 Hong Kong dollars per share (including tax).
In 2025, the company achieved first-year premiums exceeding 4.5 billion RMB, a year-on-year increase of 49.9%; the total premiums exceeded 11.2 billion RMB for the first time, a year-on-year increase of 37%.
While achieving rapid growth in premiums, the company also focused on market trends in product structure, deepening its layout in the dividend product sector. During the reporting period, first-year premiums for dividend products reached 1 billion RMB, a year-on-year increase of 341.5%, leading to a corresponding revenue increase of over 200%.
As of December 31, 2025, the total assets of the company amounted to approximately 2.4 billion RMB, an increase of 31.1% compared to the end of 2024, showing continued steady growth. The net assets of the company as of December 31, 2025, were approximately 1.3 billion RMB, compared to a net debt of 700 million RMB as of December 31, 2024. This was mainly due to the reclassification of financial instruments issued to investors as equity after the company's initial public offering on May 30, 2025, whereby the previously issued preferential rights automatically expired. The combined balance of cash and cash equivalents, low-risk financial assets measured at fair value, and deposit-like financial assets totaled approximately 845.5 million RMB, an increase of 36.8% compared to the end of 2024, indicating sufficient asset liquidity.
Related Articles

ALPHAMAB-B(09966) releases annual performance, with a net loss of 114 million RMB in the year, turning from profit to loss year-on-year.

AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.

SIMCERE PHARMA (02096) plans to acquire all equity of Shanghai Xiansheng Diagnostic Technology for 30.76 million yuan, aiming to create an open innovation exchange center.
ALPHAMAB-B(09966) releases annual performance, with a net loss of 114 million RMB in the year, turning from profit to loss year-on-year.

AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.

SIMCERE PHARMA (02096) plans to acquire all equity of Shanghai Xiansheng Diagnostic Technology for 30.76 million yuan, aiming to create an open innovation exchange center.






